InvestorsHub Logo
icon url

WolfofMia

02/10/22 6:38 AM

#350452 RE: Gator328 #350440

These concerns have been discussed before.

There are many ways to reprice the drug once approved for AD.

Our pricing scheme might change from rare diseases schemes of high tags do to low volume of patients.

To a lower tags at a much much higher volume of patients with AD, PDD, Autism approval etc.

By then we will charge less and make way more on the volume itself, but first we price it for the indication we are getting approved.

Unless this miraculous PA for AD happens in Australia, the order of approval should be Rett-adults, Rett-kids, AD/PDD/PD/etc
icon url

attilathehunt

02/10/22 12:01 PM

#350586 RE: Gator328 #350440

“ Rett patients will understandably ask for it off-label and will do all they can not to pay 10000x more”

It may be difficult for Rett patients to swallow the off label pill…so they may have to stick with oral version.